UNSPSC 51144107: Amphetamine aspartate

This classification denotes a cns stimulant with the molecular formula 2C9H13N.C4H7NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H527KAP6L5, chemically known as l-aspartic acid, compd. with alpha-methylbenzeneethanamine (1:2) but more generally known as amphetamine aspartate, which bears US NIH Compound Identifier 32892. European Medicines Agency schedules Amphetamine aspartate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33384.

Most nations, for tariff and trade purposes, schedule amphetamine aspartate under HS 29214600. As of Q4 2014, AMPHETAMINE ASPARTATE remains US FDA's Preferred Term for this commodity. Amphetamine aspartate bears US NLM identifiers UMLS ID C0724524 and NCI Concept Code C61636. SMILES: CC(CC1CCCCC1)N.CC(CC1CCCCC1)N.C([C@@H](C(=O)O)N)C(=O)O.

UNSPSC 51144107 Amphetamine aspartate, a Commodity code, spans controlled-substance pharmaceuticals that state and local health and human services agencies procure for community health programs, emergency response, and inmate care. Recent solicitations under this code show state and local governments buying naloxone for opioid overdose reversal, generic multi-source pharmaceuticals through cooperative purchasing vehicles, and direct-to-manufacturer prescription fulfillment programs. The issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Procurement routes vary from competitive sealed bidding (IFB) for specific units to Request for Proposal (RFP) processes establishing framework agreements with multiple manufacturers and Request for Information (RFI) phases to test market capacity before formal solicitation.

Recent activity clusters in Florida and Texas, with broader participation through multi-state cooperative vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to Sanford, Florida and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to assess vendor capacity for direct-to-manufacturer prescription programs outside existing pharmacy benefit manager arrangements. MMCAP, administered by the Minnesota Department of Administration, released an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline and July 1, 2026 contract effective date, requiring vendors to work through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and maintain cGMP certification and Drug Supply Chain Security Act compliance.